期刊
ACS BIOMATERIALS SCIENCE & ENGINEERING
卷 7, 期 4, 页码 1496-1505出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.1c00008
关键词
biomimetic nano-erythrocyte; tumor targeting; chemotherapy; biological barriers
资金
- National Natural Science Foundation of China [81874304, 21160002]
The study demonstrates that a biomimetic drug delivery system named NE@DOX-Ang2 can enhance the chemotherapy of breast cancer by utilizing nano-erythrocytes encapsulating doxorubicin and surface modified with a targeted angiopep-2 peptide. This system shows strong ability to cross biological barriers, increased half-life compared to conventional liposomes, and exhibits excellent tumor-targeting and antitumor effects in vitro and in vivo.
Overcoming multiple biological barriers, including circulation time in vivo, tumor vascular endothelium, reticuloendothelial system (RES), extracellular matrix (ECM), etc., is the key to improve the therapeutic efficacy of drug delivery systems in treating tumors. Inspired by the ability of natural erythrocytes to cross multiple barriers, in this study, a biomimetic delivery system named NE@DOX-Ang2 was developed for enhancing the chemotherapy of breast cancer, which employed nano-erythrocyte (NE) encapsulating doxorubicin (DOX) and surface modification with a targeted angiopep-2 peptide (Ang2). NE@DOX-Ang2 enhanced the capacity to cross biological barriers in a three-dimensional (3D) tumor spheroid model and in vivo in mice. Compared with a conventional drug delivery system of liposomes, the half-life of NE@DOX-Ang2 increased approximately 2.5 times. Moreover, NE@DOX-Ang2 exhibited excellent tumor-targeting ability and antitumor effects in vitro and in vivo. Briefly, the prepared nano-erythrocyte drug carrier has features of favorable biocompatibility and low immunogenicity and the advantage of prolonging the half-life of drugs, which may provide a novel perspective for development of clinically available nanomedicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据